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ABSTRACT 
A new, simple, accurate and economic reverse-phase HPLC method has been developed for quantification of Oxymetazoline Hydrochloride in 
nasal spray formulations. This developed method has been validated according to International Conference on Harmonization (ICH) guideline 
with respect to system suitability, specificity, precision, linearity, accuracy, and robustness. An isocratic condition of mobile phase Phosphate 
buffer (pH 3.0): Acetonitrile in a ratio of 60:40, v/v at a flow rate of 1.0 mL/minute over RP C18 (octadecylsilane (ODS), 25 0 × 4.6 mm, 5 µm, 
ECLIPSE X DB C-18) column at ambient temperature was maintained. This method is specific and showed excellent linear response with 
correlation coefficient (R2) values of 0.999, which was within the limit of correlation coefficient (R2 0.995). A  simple  and accurate reversed-
phase  HPLC  method  for  the  analysis  of  Oxymetazoline Hydrochloride in  nasal  spray formulations was developed and validated 
successfully. 
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1. INTRODUCTION 
Asthma is a chronic disease that inflames the airways (i.e. 
the small tubes, called bronchi) which carry air in and out of 
the lungs. In asthmatic patient, the bronchi will be inflamed 
and more sensitive than normal and produce extra mucus. 
This can make breathing difficult due to reversible airflow 
obstruction, or bronchospasm, and trigger coughing, 
wheezing and shortness of breath.  
The cause of asthma is probably due to a combination of the 
following factors: 
Environmental: allergens (e.g., house dust mites, animal fur 
and pollen), occupational irritants (e.g. chemical fumes, 
gases, dust or other substances on the job), tobacco smoke, 
respiratory (viral) infections, strong emotional expressions 
and drugs (e.g. aspirin and beta blockers). 
Genetic (inherited): usually occurs in children. The chances of 
developing asthma are increased if the patients’ family 
members or relatives have asthma and other allergic 
conditions such as atopic dermatitis and hay fever1. Hay 
fever also known as Allergic rhinitis, is a type 
of inflammation in the nose which occurs when the immune 
system overreacts to allergens in the air2. 
Antiasthmatic drugs are used for the treatment of asthma. 
They may be useful either in the treatment or prevention of 
asthma attacks3. Asthma and allergic rhinitis are related 
health conditions. Effective treatment for allergic rhinitis 
may reduce the chance of severe asthma attacks, and make 
the lungs work better4. People those having both asthma and 
allergic rhinitis should use both a preventer nasal spray and 
an asthma preventer inhaler regularly. The addition of 
Oxymetazoline adds to the effectiveness of Fluticasone 
furoate in the treatment of perennial allergic rhinitis5.  
Oxymetazoline is available over-the-counter as a topical 
decongestant in the form of Oxymetazoline hydrochloride 
in nasal sprays such as Otrivin, Afrin, Operil, Dristan, 
Dimetapp, Oxyspray, Facimin, Nasivin, Nostrilla.It is used to 
relieve nasal discomfort caused by colds, allergies, and hay 
fever6. 
Its molecular formula is C16H24N2O•HCl with the following 
chemical structure:  
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Figure 1: Chemical structure of Oxymetazoline 
hydrochloride 
Oxymetazoline hydrochloride occurs as a white, almost 
odorless, crystalline powder. It has a molecular weight of 
260.38 g/mol. It has a melting point of about 182 °C. It is 
freely soluble in water and methanol7. 
In present, official method for quantification of 
Oxymetazoline hydrochloride is available and that is of 
titrimetric method 8, which is time consuming and highly 
sensitive, but simple, accurate and precise reverse phase 
HPLC method is not available. Our interest of work was to 
develop suitable HPLC method required for analysis and 
characterization of Oxymetazoline hydrochloride from nasal 
spray formulation. 
2. MATERIALS AND METHODS 
2.1 Materials and Reagents 
Oxymetazoline hydrochloride working standard and Placebo 
were a kind gift of Shalini Chemicals, Aurangabad, 
Maharashtra. Test samples purchased from market store. 
HPLC grade  Acetonitrile, Potassium  dihydrogen  phosphate 
and  HPLC Water were purchased from Ranbaxy Fine 
Chemicals Ltd., India. 
2.2 HPLC system 
High-performance  liquid  chromatographic  system  (Agilent 
(1100) Gradient System)   equipped  with  UV–visible  
detector was  used  for  the analysis. The data were recorded 
using Chemstation 10.02 software.  
2.3 Preparation of mobile phase 
Dissolved 6.8 gm of KH2PO4 in to 1000 ml water and 
sonicated to dissolved (pH observed 4.41), adjusted to pH 
3.00 with diluted Orthophosphoric acid solution. Buffer 
filtered through a 0.45-µm PVDF membrane filter and 
sonicated to degas. Prepared a mixture of Buffer (pH 3.0) : 
Acetonitrile (60:40), v/v, sonicated to degas. 
2.4 Preparation of standard solution (40 PPM) 
Accurately weighed and transferred 40 mg of Oxymetazoline 
hydrochloride working standard in to 100 mL volumetric 
flask, added about 30 mL of  Acetonitrile and sonicated to 
dissolve, wait to cool and diluted up to mark with diluent. 
Transferred 5 mL of this solution in to 50 mL volumetric and 
diluted up to mark with Mobile Phase. 
2.5 Preparation of sample solution (40 PPM) 
Brand Name:- Naselin Nasal Spray ( CIPLA LTD)  
Transferred 2.0 mL of Sample solution in to 25 mL 
volumetric flask, added about 15 mL of mobile phase and 
sonicated to mixed properly, diluted up to mark with mobile 
phase, and the samples were analyzed using the proposed 
analytical methods. 
2.6 Preparation of Placebo solution (8 PPM) 
Accurately weighed and transferred 20 mg of Placebo 
powder  in to 200 mL volumetric flask, added about 100 mL 
of  mobile phase and sonicated to dissolve, wait to cool and 
diluted up to mark with mobile phase. Transferred 2 mL of 
this solution in to 25 mL volumetric and diluted up to mark 
with Mobile Phase. 
2.7 Chromatographic conditions 
The analysis was carried out at temperature 27° C under 
isocratic condition. The mobile phase was run at  a  flow  
rate  of  1.0  mL/minute  for  10  min.  The injection volume 
was 20 µL for  blank, placebo, standard and sample solution . 
Before analysis, every standard and sample were filtered 
through 0.45 µm Nylon syringe filter. The analysis was 
monitored with UV detection at 203 nm. 
2.8 Method validation   
Method validation is the process used to confirm that the 
analytical procedure employed for a specific test is suitable 
for its intended use. Results from method validation can be 
used to judge the consistency, quality and reliability of 
analytical results; it is an integral part of any good analytical 
practice. Typical parameters verified in validation of 
analytical method are listed in table 1. ICH Q2(R1)9 is  
considered  the  primary  reference  for  recommendations  
and  definitions  on  validation characteristics for analytical 
procedures. 
Table 1: Typical parameters verified in method 
validation 
Sr No Validation parameter 
1 System suitability 
2 Specificity 
3 Precision 
4 Accuracy 
5 Linearity 
6 Robustness 
 
2.8.1 System suitability 
System suitability is an essential parameter of any analytical 
method development. The tests are based upon the concept 
that the equipment, electronics, analytical operations and 
samples to be analyzed constitute an integral system that 
can be evaluated as such. System suitability test ensure 
adequate performance of the chromatographic system and 
quality of the method for accurate results. It is required to 
done before every sample analysis. To determine system 
suitability Oxymetazoline Hydrochloride standard solution 
was prepared and injected for six times into HPLC system. 
The mean, SD and % RSD for peak areas of Oxymetazoline 
was calculated. 
2.8.2 Specificity 
Assuring specificity is the first step in developing and 
validating a good analytical method10. Specificity ensures the 
identity of the analyte of interest. The ICH documents define 
specificity as the ability to measure accurately and 
specifically the analyte of interest in the presence of other 
components that may be expected to be present in the 
sample matrix such as impurities and degradation products. 
The placebo solution containing excipients without 
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Oxymetazoline were injected. To evaluate the specificity of 
the method blank, placebo and sample solution were 
injected. 
2.8.3 Precision 
Precision is the degree of agreement among individual test 
results when an analytical method is used repeatedly to 
multiple samplings of a homogeneous sample. The precision 
of an analytical procedure is usually expressed as the 
standard deviation or relative standard deviation 
(coefficient of variation) of a series of measurements. 
Precision may be a measure of either the degree of 
reproducibility  or  of  repeatability  of  the  analytical  
procedure  under  normal  operating  conditions. The 
precision of the assay method was assessed with respect to 
repeatability and reproducibility. Repeatability is also 
termed intra-assay precision. Sample of a single batch were 
prepared six times and analyzed as per test method, % assay 
of Oxymetazoline for six samples calculated for method 
precision. 
2.8.4 Accuracy 
The accuracy of an analytical procedure is the closeness of 
test results obtained by that procedure to the true value.  
The accuracy of  an  analytical  procedure  should be 
established  across its range. Accuracy should be reported as 
percent recovery by the assay of known added amount of 
analyte in test solution. In this study, successive analysis 
(n=3) for three different concentrations of standard 
mixtures (80, 100 and 120%) was carried out to determine 
the accuracy of proposed method. 
2.8.5 Linearity 
The linearity of an analytical procedure is its ability within a 
given range to obtain test results which are directly 
proportional to the concentration (amount) of analyte in the 
sample. Linearity has been performed on different 
concentrations within 25–150% of the nominal standard 
concentration. The linearity of this proposed method was 
evaluated by using calibration curve to calculate the 
coefficient of correlation, slope, and intercept values. 
2.8.6 Robustness 
Robustness is a capacity of the method to remain unaffected 
by small deliberate, variations in method parameters. 
Robustness is an indication of the reliability of the analytical 
method during normal usage. The effect of the following 
deliberate changes in chromatographic conditions was 
monitored: Detector wavelength±2 nm, Flow rate±10%, 
Temperature±2 °C, and pH  of  Buffer solution±0.1. 
3. RESULTS AND DISCUSSION 
3.1 System suitability 
The results of system suitability observed within acceptable 
limits as shown in table 2. 
Table 2:  Results from the determination of system 
precision 
Standard No Peak area of Oxymetazoline 
1 6954 
2 6920 
3 6998 
4 6941 
5 6932 
6 6943 
Mean 6948 
SD 27.02 
%RSD 0.39 
Values are expressed for six replicate (n=6) 
 
Table 3: Data from Method precision 
Sample No % Assay of Oxymetazoline 
1 101.3 
2 100.7 
3 100.4 
4 101.5 
5 101.1 
6 101.2 
Mean 101.0 
SD 0.42 
% RSD 0.42 
Values are expressed as mean± standard deviation of six 
samples (n=6) 
3.2 Specificity 
Accuracy should be reported as percent recovery by the 
assay of known added amount of analyte in the sample
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a)Blank 
 
b)Placebo 
 
c)Sample solution 
 
Figure 2: HPLC Chromatogram a)Blank, b)Placebo and c)Sample solution 
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3.3 Accuracy 
Known amount of Oxymetazoline hydrochloride was spiked 
in placebo at about 80,100 and 120% of test concentration. 
The amount of Oxymetazoline hydrochloride recovered was 
quantified as per developed method.  The % recovery was 
calculated from the amount found and actual amount added. 
The results are tabulated in table 4.  The overall recovery of 
Oxymetazoline hydrochloride in the samples was in between 
98.0  to 102.0% (RSD<2%) which  is satisfactory for 
quantification of Oxymetazoline hydrochloride  in nasal 
spray formulations. 
 
Table 4: Accuracy evaluation of the proposed method for quantification of Oxymetazoline 
Spiked level (%)/ 
Sample No 
Actual amount of 
API added(mg) 
Amount of 
Oxymetazoline  
found (mg) 
% Recovery Mean SD %RSD 
80% Sample-1 0.8015 0.7907 98.6 
98.8 0.16 0.16 80% Sample-2 0.8015 0.7926 98.9 
80% Sample-3 0.8015 0.7931 98.9 
100% Sample-1 1.0019 0.9974 99.6 
99.5 0.07 0.07 100% Sample-2 1.0019 0.9966 99.5 
100% Sample-3 1.0019 0.9962 99.4 
120% Sample-1 1.2023 1.2092 100.6 
100.5 0.06 0.06 120% Sample-2 1.2023 1.2086 100.5 
120% Sample-3 1.2023 1.2079 100.5 
Values are expressed as mean± standard deviation of replicate (n=3) 
 
3.4 Linearity 
A graph was plotted with concentration (in µg/ml) of 
Oxymetazoline hydrochloride on X-axis and peak areas of 
Oxymetazoline on Y-axis. The results are tabulated in table 5 
and graphically represented in figure 3.Excellent linear 
response has been observed with correlation coefficient (R2) 
values of 0.999, which was within the limit of the correlation 
coefficient (R2=0.995). 
 
 
Fig.3: Linearity plot for Oxymetazoline 
Table 5: Results of linearity 
Spike level in 
% 
Concentration 
(mcg/mL) 
Average Area 
(N=2) 
25 10.03 1695 
50 20.06 3408 
75 30.09 5112 
100 40.12 6927 
125 50.15 8539 
150 60.18 10399 
Slope 173 
Y-Intercept -59.47 
Correlation Coefficient ® 0.99989 
 
R² = 0.9997 
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3.5  Robustness results 
Robustness of the method was verified by deliberately applying the following chromatographic conditions as shown in table 6 
i.e. 
I By changing the wavelength by ±2 nm 
II By changing the flow rate by ±10% 
III By changing the column oven temperature by ±2 °C 
IV By changing the pH of buffer used for mobile phase by ±0.1 unit 
 
Table 6: Robustness experiment 
Sr. 
No. 
Robustness Parameter 
Retention Time 
(min) 
Tailing 
factor 
Theoretical 
plates 
% RSD of  Standard 
solution 
1 Wavelength 201 nm 3.77 0.96 7911 0.06 
2 Wavelength 205 nm 3.78 0.96 7904 0.08 
3 Flow rate (0.90 mL/min) 4.18 0.86 9321 0.12 
4 Flow rate (1.10 mL/min) 3.59 0.88 8831 0.07 
5 Column Temp 25° C 4.00 0.89 7869 0.04 
6 Column Temp 29° C 4.00 0.89 7854 0.09 
7 Buffer pH 2.9 4.01 0.91 7452 0.05 
8 Buffer pH 3.1 4.03 0.89 7519 0.11 
 
3.6 Estimation of formulations 
The observation for assay of Oxymetazoline hydrochloride in 
nasal spray formulations ranged from 100.4 % to 101.5 %, 
with a standard deviation of not more than 0.42%.  The 
assays for the formulations were observed same as 
mentioned in the label claim, indicating that the suitability of 
the proposed analytical method.  The estimated drug content 
with low values of standard deviation established the 
precision of the proposed method. 
4.0 DISCUSSION 
Development  of  an  analytical  method  for  assessment  of  
drugs  in  the  pharmaceutical  dosage  form  is  of most  
necessity to confirm  the  quality of  nasal formulations with 
respect to assay and spray  content uniformity.  
Development and validation of Oxymetazoline 
hydrochloride by high performance liquid chromatography 
is reported in literature11,12 but we have observed  below 
drawbacks in hose analytical methods which are as follows: 
 Almost all methods are time consuming which affects 
on productivity in routine sample analysis. 
 Usage of organic solvent more than 45% is not at all 
cost effective and also affects on chromatographic 
conditions; buffer salts  may precipitate  
 Complex methodology effects on accuracy of analytical 
method and man power utilization in pharmaceutical 
industry. 
Our developed HPLC analytical method for estimation of 
Oxymetazoline in nasal spray formulations has used 
minimum amount of organic solvents which is cost effective, 
economic and environment friendly. The wavelength used in 
proposed analysis method also efficient to trace unexpected 
solvent peaks qualitatively.  
5.0 CONCLUSIONS 
A very simple reversed-phase HPLC method for the routine 
and stability analysis of Oxymetazoline hydrochloride in 
nasal spray formulations was developed and validated. The 
proposed method is new, simple, accurate, precise, robust, 
specific and linear over the analysis ranges and also able to 
resolve the drug from excipients in a short analytical run 
time. 
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